Preprint / Version 1

Failures in AD Clinical Trails: How will they change the future?


  • Aleeza Dhillon Valley Stream North High School



alzheimer's disease, clinical trials, neuroscience


This paper investigates the reasons why clinical trials for treatments of Alzheimer's disease (AD) have failed and makes recommendations for improvement. The intricate AD pathophysiology, poor patient selection, inadequate dosage, and inappropriate trial design are a few of the factors contributing to clinical trials' low success rates. The research examines the use of imaging biomarkers, Aβ and tau proteins, and other biomarkers in patient selection and diagnosis. It also talks about the ε4 allele and APP gene mutations as genetic risk factors for AD.  The article highlights the requirement for a greater understanding of the underlying mechanisms causing AD and the creation of specialized treatment procedures that address various parts of the illness.


"Aducanumab (marketed as Aduhelm) Information." FDA, 2021,

Beshir, Semira Abdi. "Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review." International Journal of Alzheimer's Disease, 2022, Accessed 23 Apr. 2023.

Cambridge. "Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer's Disease." Eisai, 2019, Accessed 23 Apr. 2023.

Chen, Guo-fang. "Amyloid Beta: Structure, Biology and Structure-Based Therapeutic Development." APS, 2017, Accessed 23 Apr. 2023.

Cummings, Jeffrey. "Alzheimer's Disease Drug Development Pipeline: 2020." Wiley Online Library, 11 July 2020, pp. 1-29, Accessed 23 Apr. 2023.

DeTure, Michael A. "The Neuropathological Diagnosis of Alzheimer's Disease." National Library of Medicine, 2 Aug. 2019, pp. 1-18, Accessed 23 Apr. 2023.

Doody, Rachelle. "Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease." New England Journal of Medicine, 2014,

Ellison, Tim S. "Outcome Measures for Alzheimer's Disease: A Global Inter-Societal Delphi Consensus." The Journal of Alzheimer's Association, 20 Dec. 2022, Accessed 23 Apr. 2023.

Fagan, Anne M. "Cerebrospinal Fluid Biomarkers of Alzheimer's Disease." NIH, 2010, pp. 1-19, Accessed 23 Apr. 2023.

Fogel, David B. "Factors Associated with Clinical Trials That Fail and Opportunities for Improving the Likelihood of Success: A Review." Elsevier, 2018, Accessed 23 Apr. 2023.

Hansson, Oskar. "Advantages and Disadvantages of the Use of the CSF Amyloid β (Aβ) 42/40 Ratio in the Diagnosis of Alzheimer's Disease." Alzheimer's Research and Therapy, 2019, pp. 1-15, Accessed 23 Apr. 2023.

Honig, Lawrence S. "Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease." New England Journal of Medicine, 2018, Accessed 23 Apr. 2023.

Lemere, Cynthia A. "Can Alzheimer Disease Be Prevented by Amyloid-β Immunotherapy?" NIH, 2010,

Nojima, Hisashi. "Clinical Utility of Cerebrospinal Fluid Biomarkers Measured by LUMIPULSE System." ANNALS, 2022, pp. 1-12, Accessed 23 Apr. 2023.

Qiu, Tian. "Aβ42 and Aβ40: Similarities and Differences." Peptide Science, 28 May 2015, pp. 522-29, Accessed 23 Apr. 2023.

Raulin, Ana-Caroline. "ApoE in Alzheimer's Disease: Pathophysiology and Therapeutic Strategies." BMC, 2022, pp. 1-26, Accessed 23 Apr. 2023.

Srivastava, Sukriti. "Alzheimer's Disease and Its Treatment by Different Approaches: A Review." European Journal of Medicinal Chemistry, 2021, Accessed 23 Apr. 2023.

Suppiah, Subapriya. "The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer's Disease—Review of Literature and Interesting Images." MDPI, 2019, Accessed 23 Apr. 2023.

Vaz, Miguel. "Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities." NCBI, 2022, Accessed 23 Apr. 2023.

Wenk, Gary L. "Neuropathologic Changes in Alzheimer's Disease." National Library of Medicine, 2003, Accessed 23 Apr. 2023.

Yiannopoulou, Konstantina G. "Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research." Biomedicines, 2019, pp. 1-16, Accessed 23 Apr. 2023.